Clearing the Air: Recognizing the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions

 

 

PROGRAM OVERVIEW

In the area of severe asthma, an emerging understanding of disease pathophysiology has identified therapeutic targets leading to better tolerated and more selective treatments. Biologics now fill a previously unmet need for effective treatment options for patients with eosinophilic-mediated respiratory disease. However, there are a number of eosinophil-mediated lung diseases associated with severe asthma that remain poorly understood, including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Understanding the drivers of diseases associated with and sometimes concomitant to severe asthma is critical to effective management, as is the ability to identify which patients might benefit from available therapeutic agents. This interactive program was designed to increase the clinician’s understanding of severe eosinophilic diseases that target the lungs and enable them to differentiate between available treatments to facilitate improved symptoms, lighter disease burden, fewer exacerbations, and reduced oral corticosteroids reliance.

FACULTY

Mark FitzGerald, MB, MD, FRCPC
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia

Release date: June 25, 2020
Expiration date: June 25, 2021
Estimated time to complete activity: 1.0 hour

 

TARGET AUDIENCE

This educational initiative has been designed for pulmonologists, allergists, fellows, medical residents, nurse practitioners, physician assistants, nurses, and other allied health care professionals who manage patients with asthma and other eosinophilic-associated diseases.

LEARNING OBJECTIVES

Upon completion of this free educational activity, participants should be able to:

  • Describe the role of eosinophilia in severe asthma and EGPA
  • Explain why severe asthma comorbidities and rare orphan diseases have an impact on treatment of severe asthma
  • Differentiate between available biologic therapies and evaluate their impact on lung function, asthma exacerbations, and dependence on oral corticosteroids
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of June 25, 2020 through June 25, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education designates this enduring material for a maximum of 1.00 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0530-9999-20-069-H01-P)

This is a knowledge-based activity.

CONTACT INFORMATION

For information about the ANCC or ACPE accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education (Integrity CE) and Global Education Group (Global) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity CE and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.

Mark FitzGerald, MB, MD, FRCPC
Consulting Fees:  AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Fees for Non-CME/CE: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Contracted Research/Funds paid directly to UBC:  AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Gossamer Bio, Novartis Pharmaceuticals Corporation, Sanofi Regeneron

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Amy Khalil, Liddy Knight, Ashley Marostica, RN, MSN, Patima Tanapat, PhD,  reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and GlaxoSmithKline, do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education or GlaxoSmithKline. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

Minimum System Requirements
Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

This CME activity for ACCME credit is provided by Integrity Continuing Education.

This CE activity for ANCC and ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an educational grant from GlaxoSmithKline LLC.

Continue to Pretest